Blood Banks Charged ₹ 147 Cr From Patients In Six Years In Mumbai, Says RTI

Mumbai : Complaints were made to the State Blood Transfusion Council that blood banks were charging extra fees from patients and their relatives for providing blood and its components. Taking cognizance of these complaints, the State Blood Transfusion Council had decided in 2020 to levy a fine of five times more than the fee charged by the concerned blood banks. But earlier, the State Blood Transfusion Council and the Food and Drug Administration had tightened their belts to impose fines on looting by blood banks. Accordingly, only 20 percent of the additional fee was directed to be deposited with the council. Accordingly, when the council announced the penalty amount, the blood banks objected to it. Therefore, the council appointed an accounting firm to audit the accounts. According to the information provided by this company, it was revealed that 22 private blood banks in Mumbai collected INR 147 crore from additional charges. State Blood Transfusion Council provided this information to activist Chetan Kothari through Right to Information.

Kokilaben Dhirubhai Ambani Hospital in Andheri collected the highest additional charges of 3 crore 4 lakh 18 thousand 965 rupees. Under that, Hinduja Hospital in Mahim has collected 2 crore 32 lakh 45 thousand 640 rupees, Jaslok Hospital has collected 2 crore 26 lakh 75 thousand 850 rupees additional charges. The council has imposed a 20 percent penalty on 22 blood banks in Mumbai for charging extra. Accordingly, an amount of ₹ 27.63 crore has been levied as penalty. This fine amount has been recovered from these blood banks.

According to the decision taken by the State Blood Transfusion Council in 2020, a fine of five times the additional fee charged by blood banks will be levied. From that, the amount will be returned to the patients and the remaining amount will be deposited with the Council. However, there is no provision to refund any amount to the patient from the penalty on additional charges during the period 2014 to 2019.

Related Posts

  • Pharma
  • July 16, 2025
  • 290 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 94 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates